BPI-27336

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBPI-27336
Drug Alias NameBPI-27336
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsExtracellular-signal-regulated kinase 2 inhibitors
TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2
Therapy Area/IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBetta Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBetta Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A